https://www.selleckchem.com/pr....oducts/17-AAG(Geldan
9 (95% confidence interval [CI] = 4.6-7.2) months. Patients who had a CN had a median OS of 16.6 (95% CI = 14.2-19.1, p 0.001) months, whereas patients who had surgery with curative intent had a median OS of 51.3 (95% CI = 36.0-66.6, p 0.001) months. The survival benefit of CN and metastasectomies remained significant in all medical therapy subgroups and in both of the applied multivariable statistical models. Surgical treatment of metastatic renal cell cancer is associated with a significant survival benefit in p
إعجاب
علق
شارك
